1Bendele RA,Richardson FC.Adefovir nephrotoxicity and mitochondrial DNA depletion[].Human Pathology.2002
2Ho ES,Lin DC,Mendel DB,et al.Cytotoxicity of antiviral nucle-otides adefovir and cidofovir is induced by the expression of human renal organic anion transporter 1[].Journal of the American Society of Nephrology.2000
3Cullen JM,Li DH,Brown C,et al.Antiviral efficacy and pharmaco- kinetics of oral adefovir dipivoxil in chronically woodchuck hepatitis virus-infected woodchucks[].Antimicrobial Agents and Chemotherapy.2001
4Delaugerre C,Marcelin AG,Thibault V,Peytavin G,et al.Human immunodeficiency virus(HIV) Type 1 reverse transcriptase resistance mutation in hepatitis B virus(HBV)-HIV-coinfected patients treated for HBV chronic infection once daily with 10 milligrams of adefovir dipivoxil combined with lamivudine[].Antimicrobial Agents and Chemotherapy.2002
5Nobel S,Goa KL.Adefovir dipivoxil[].Drugs.1999
6Julander JG,Sidwell RW,Morrey JD.Characterizing antiviral activity of adefovir dipivoxil in transgenic mice expressing hepatitis B virus[].Antiviral Research.2002
7Yang H,Westland CE,Delaney WE,et al.Resistance surveillance in chronic hepatitis B patients treated with Adefovir dipivoxil for up to 60 weeks[].Hepatology.2002
8Perrillo R. Schiff E.Yoshida E,et al.Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants[].Hepatology.2000
9Marcellin P,Chang TT,Lim SG,et al.Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B[].The New England Journal of Medicine.2003
10Hadziyannis SJ,Tassopoulos NC,Heathcote EJ,et al.Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B[].The New England Journal of Medicine.2003
8Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association. 42 Dongsi Xidajie,Beijing 100710,China.慢性乙型肝炎防治指南[J].中华肝脏病杂志,2005,13(12):881-891. 被引量：1931
10Hadziyannis S, Tassopoulos N, Chang TT, et al. Three year study of adefovir dipivoxil (ADV) demonstrates sustained efficacy in presumed prec ore mutant chronic hepatitis B patients in a long-term safety and efficacy study[J]. J Hepatol, 2004, 40(Suppl 1):S17.
